A Phase III Randomized Trial of Gemcitabine (NSC 613327) Plus Docetaxel (NSC 628503) Followed by Doxorubicin (NSC 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Docetaxel (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Filgrastim; Pegfilgrastim
- Indications Uterine cancer
- Focus Therapeutic Use
- 13 May 2017 This trial has been discontinued in Spain.
- 11 May 2017 This trial has been discontinued in the Netherlands.
- 14 Apr 2017 This trial has been completed in France (End date: 2017-03-23) as per European Clinical Trials Database record.